Current Liabilities decreased faster than Arcellx Inc 's Cash & cash equivalent, this led to improvement in Arcellx Inc 's Quick Ratio to 4.32, Quick Ratio remained below Arcellx Inc average.

Within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Quick Ratio than Arcellx Inc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 666 to 707.

Explain Quick Ratio?
How much Cash & cash equivalents ACLX�s has?
What are ACLX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ACLX Quick Ratio	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	-16.91 %	-13.59 %	38.01 %	4.23 %	6.06 %
Y / Y Cash & cash equivalent Change	-23.33 %	-19.66 %	-12.31 %	-5.34 %	-16.33 %
Quick Ratio MRQ	4.32	3.9	3.72	4.83	4.68
ACLX's Total Ranking	# 707	# 666	# 634	# 499	# 241
Seq. Current Liabilities Change	-11.99 %	-2.84 %	8.35 %	-10.32 %	-8.47 %
Seq. Cash & cash equivalent Change	-2.39 %	1.83 %	-16.6 %	-7.51 %	2.28 %

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 66
Healthcare Sector	# 315
Overall Market	# 707

Quick Ratio Statistics
High	Average	Low
14.62	5.63	2.54
(Mar 31 2022)		(Sep 30 2023)

Financial Statements
Arcellx Inc 's Current Liabilities	$ 104 Millions	Visit ACLX's Balance sheet
Arcellx Inc 's Cash & cash equivalent	$ 450 Millions	Visit ACLX's Balance sheet
Source of ACLX's Sales		Visit ACLX's Sales by Geography

Cumulative Arcellx Inc 's Quick Ratio

ACLX's Quick Ratio for the trailling 12 Months

ACLX Quick Ratio	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-0.37 %	5.91 %	1.88 %	-16.61 %	-25.25 %
Y / Y Cash & cash equivalent TTM Growth	-15.28 %	-13.59 %	-3.33 %	-0.02 %	3.23 %
Quick Ratio TTM	4.18	4.28	4.34	4.8	4.91
Total Ranking TTM	# 1976	# 2746	# 1730	# 2804	# 1726
Seq. Current Liabilities TTM Growth	-4.43 %	-3.75 %	7.25 %	0.99 %	1.59 %
Seq. Cash & cash equivalent TTM Growth	-6.7 %	-5.23 %	-2.86 %	-1.36 %	-4.84 %

Quick ratio ranking by company, industry and sector >> Back to ACLX Financial Strength Comparisons >> Go to Compare ACLX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ACLX's Current Liabilities to $104.20 millions, cumulative Quick Ratio to 4.18 below the ACLX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 63 other companies have achieved higher Quick Ratio than Arcellx Inc . While Quick Ratio overall ranking has improved so far to 1976, from total ranking during the twelve months ending third quarter 2025 at 2746.

Explain Quick Ratio?
How much Cash & cash equivalents ACLX�s has?
What are ACLX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 64
Healthcare Sector	# 454
Within the Market	# 1976

trailing twelve months Quick Ratio Statistics
High	Average	Low
7.55	4.62	3.14
(Dec 31 2022)		(Sep 30 2023)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Immunovant Inc	10.40	$ 713.971 Millions	$ 68.677 Millions
Cullinan Therapeutics Inc	10.22	$ 377.896 Millions	$ 36.961 Millions
X4 Pharmaceuticals Inc	9.82	$ 252.998 Millions	$ 25.757 Millions
Molecular Partners Ag	9.44	$ 104.149 Millions	$ 11.027 Millions
4d Molecular Therapeutics Inc	9.15	$ 402.655 Millions	$ 43.985 Millions
Prokidney Corp	9.10	$ 270.017 Millions	$ 29.671 Millions
Sab Biotherapeutics Inc	9.04	$ 96.592 Millions	$ 10.681 Millions
Denali Therapeutics Inc	8.82	$ 867.879 Millions	$ 98.351 Millions
Artiva Biotherapeutics Inc	8.25	$ 108.008 Millions	$ 13.087 Millions
Black Diamond Therapeutics Inc	8.18	$ 128.652 Millions	$ 15.731 Millions
Zura Bio Limited	8.02	$ 109.407 Millions	$ 13.647 Millions
Aura Biosciences Inc	7.85	$ 144.241 Millions	$ 18.383 Millions
Replimune Group Inc	7.76	$ 483.804 Millions	$ 62.362 Millions
Allogene Therapeutics Inc	7.70	$ 250.210 Millions	$ 32.514 Millions
Compugen Ltd	7.67	$ 145.640 Millions	$ 18.999 Millions
Voyager Therapeutics Inc	7.40	$ 196.447 Millions	$ 26.541 Millions
Scholar Rock Holding Corp	7.37	$ 367.563 Millions	$ 49.869 Millions
Krystal Biotech Inc	7.27	$ 827.791 Millions	$ 113.861 Millions
Metagenomi Therapeutics Inc	7.01	$ 160.799 Millions	$ 22.933 Millions
Fennec Pharmaceuticals Inc	7.00	$ 73.576 Millions	$ 10.518 Millions
Odyssey Therapeutics, Inc.	6.85	$ 181.358 Millions	$ 26.475 Millions
Invivyd Inc	6.64	$ 226.689 Millions	$ 34.163 Millions
Entera Bio Ltd	6.59	$ 7.108 Millions	$ 1.079 Millions
Tenaya Therapeutics Inc	6.51	$ 100.547 Millions	$ 15.436 Millions
Repligen Corp	6.51	$ 767.628 Millions	$ 117.859 Millions
Engene Therapeutics Inc	6.47	$ 193.736 Millions	$ 29.965 Millions
Acumen Pharmaceuticals Inc	6.03	$ 116.865 Millions	$ 19.391 Millions
Solid Biosciences Inc	5.99	$ 187.850 Millions	$ 31.369 Millions
Century Therapeutics inc	5.79	$ 117.114 Millions	$ 20.226 Millions
Neumora Therapeutics Inc	5.67	$ 182.530 Millions	$ 32.167 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.